Vascular smooth muscle alpha-actin expression as an indicator of parenchymal cell reprogramming in cardiac allografts

Transplantation
S V SubramanianA R Strauch

Abstract

In addition to transplant-associated vascular sclerosis, cardiac allografts also may be vulnerable to a previously unrecognized aspect of remodeling involving reactivation of fetal structural genes in the adult heart. Vascular smooth muscle (VSM) alpha-actin is encoded by a gene that normally is repressed in the ventricle during late gestation. Immunohistochemical analysis of accepted mouse cardiac allografts was performed to determine whether this fetal actin was reexpressed after transplant. VSM alpha-actin was detected within 30 days after transplant throughout the allograft myocardium, where it frequently exhibited a distinct periodicity suggestive of protein localization in sarcomeres. By 90 days after transplant, VSM alpha-actin filaments specifically accumulated in the left ventricular endocardium. Donor hearts and isografts did not express myocardial VSM alpha-actin, indicating that fetal gene activation was linked to chronic rejection. The results indicate that chronic rejection is associated with fetal muscle gene activation, which may facilitate parenchymal cell remodeling and impair graft function.

References

Jan 1, 1991·Annual Review of Physiology·T G Parker, M D Schneider
Jul 1, 1996·The Journal of Cell Biology·L Rønnov-Jessen, O W Petersen
Apr 15, 1997·Transplantation·A T ArmstrongC G Orosz
Apr 29, 1997·Proceedings of the National Academy of Sciences of the United States of America·A KumarJ L Lessard
Jul 1, 1996·Trends in Cardiovascular Medicine·L A DebruyneD K Bishop

❮ Previous
Next ❯

Citations

Feb 9, 2000·Folia Microbiologica·P RossmannA Lodererová
May 29, 2002·Cardiovascular Research·Wilfried Briest
Aug 10, 2000·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·C G Orosz
Dec 21, 2002·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Phillip RuizAndreas Tzakis
Jan 5, 2011·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Haydar K SalehPatricia A Pellikka
Mar 25, 2004·The American Journal of Pathology·Yifa ChenPeter S Heeger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.